Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/ brachyury signalling pathway in chordomas

Modern Pathology

Volumn 22, Issue 8, 2009, Pages 996-1005

  Shalaby, Asem Ae ^a,b   Presneau, Nadege ^a   Idowu, Bernadine D ^b   Thompson, Lisa ^c   Briggs, Timothy Rw ^b   Tirabosco, Roberto ^b   Diss, Timothy C ^c   Flanagan, Adrienne M ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Amplification; Brachyury; Chordoma; ETS2; FGFR; Genetics

Indexed keywords

B RAF KINASE; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2ALPHA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRACHYURY; TRANSCRIPTION FACTOR ETS 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCIDIACEA; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR GENETICS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; XENOPUS;

EID: 68249127294     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.63     Document Type: Article

References (54)

1. Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol 2008;32:572-580.
2. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11.
3. McPherson CM, Suki D, McCutcheon IE, et al. Metastatic disease from spinal chordoma: a 10-year experience. J Neurosurg Spine 2006;5:277-280.
4. Park L, Delaney TF, Liebsch NJ, et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006;65:1514-1521.
5. Edwards YH, Putt W, Lekoape KM, et al. The human homolog T of the mouse T(Brachyury) gene; gene structure, cDNA sequence, and assignment to chromosome 6q27. Genome Res 1996;6:226-233.
6. Showell C, Binder O, Conlon FL. T-box genes in early embryogenesis. Dev Dyn 2004;229:201-218.
7. Gokhale PJ, Giesberts AM, Andrews PW. Brachyury is expressed by human teratocarcinoma cells in the absence of mesodermal differentiation. Cell Growth Differ 2000;11:157-162.
8. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006;209:157-165.
9. Romeo S, Hogendoorn PC. Brachyury and chordoma: the chondroid-chordoid dilemma resolved? J Pathol 2006;209:143-146.
10. Choi KS, Cohn MJ, Harfe BD. Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation. Dev Dyn 2008;237: 3953-3958.
11. Yamaguchi T, Suzuki S, Ishiiwa H, et al. Benign notochordal cell tumors: a comparative histological study of benign notochordal cell tumors, classic chordomas, and notochordal vestiges of fetal intervertebral discs. Am J Surg Pathol 2004;28:756-761.
12. Isaacs HV, Pownall ME, Slack JM. eFGF regulates Xbra expression during Xenopus gastrulation. EMBO J 1994;13:4469-4481.
13. Nakatani Y, Yasuo H, Satoh N, et al. Basic fibroblast growth factor induces notochord formation and the expression of As-T, a Brachyury homolog, during ascidian embryogenesis. Development 1996; 122:2023-2031.
14. Schulte-Merker S, Smith JC. Mesoderm formation in response to Brachyury requires FGF signalling. Curr Biol 1995;5:62-67.
15. Ciruna BG, Schwartz L, Harpal K, et al. Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak. Development 1997;124:2829-2841.
16. Hadari YR, Gotoh N, Kouhara H, et al. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci USA 2001;98: 8578-8583.
17. Sacchi N, Watson DK, Guerts van Kessel AH, et al. Huets-1 and Hu-ets-2 genes are transposed in acute leukemias with (4;11) and (8;21) translocations. Science 1986;231:379-382.
18. Foulds CE, Nelson ML, Blaszczak AG, et al. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 2004;24:10954-10964.
19. Gibas Z, Miettinen M, Sandberg AA. Chromosomal abnormalities in two chordomas. Cancer Genet Cytogenet 1992;58:169-173.
20. Hallor KH, Staaf J, Jonsson G, et al. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 2008;98: 434-442.
21. Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26: 7158-7162.
22. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008;105:8713-8717.
23. Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008;4:71-83.
24. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-6662.
25. Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006;107: 4039-4046.
26. Hoffmann A, Czichos S, Kaps C, et al. The T-box transcription factor Brachyury mediates cartilage development in mesenchymal stem cell line C3H10T1/2. J Cell Sci 2002;115:769-781.
27. Yamaguchi TP, Harpal K, Henkemeyer M, et al. fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev 1994;8:3032-3044.
28. Fasig JH, Dupont WD, LaFleur BJ, et al. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol 2008;34:95-104.
29. Naka T, Kuester D, Boltze C, et al. Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer 2008;112:104-110.
30. Park JB, Lee CK, Koh JS, et al. Overexpressions of nerve growth factor and its tropomyosin-related kinase A receptor on chordoma cells. Spine 2007;32:1969-1973.
31. Tamborini E, Miselli F, Negri T, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006;12:6920-6928.
32. Weinberger PM, Yu Z, Kowalski D, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005;131:707-711.
33. Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-98.
34. Mehta P, Robson CN, Neal DE, et al. Fibroblast growth factor receptor-2 mutation analysis in human prostate cancer. BJU Int 2000;86:681-685.
35. Forbes S, Clements J, Dawson E, et al. COSMIC 2005. Br J Cancer 2006;94:318-322.
36. Elbauomy ES, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007;9:R23.
37. Shin EY, Lee BH, Yang JH, et al. Up-regulation and coexpression of fibroblast growth factor receptors in human gastric cancer. J Cancer Res Clin Oncol 2000;126:519-528.
38. Chen J, Williams IR, Lee BH, et al. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood 2005;106: 328-337.
39. Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19: 3309-3320.
40. Chen Y, Li X, Eswarakumar VP, et al. Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation. Oncogene 2000;19:3750-3756.
41. Kawachi K, Masuyama N, Nishida E. Essential role of the transcription factor Ets-2 in Xenopus early development. J Biol Chem 2003;278: 5473-5477.
42. Matsumoto J, Kumano G, Nishida H. Direct activation by Ets and Zic is required for initial expression of the Brachyury gene in the ascidian notochord. Dev Biol 2007;306:870-882.
43. Hsu T, Trojanowska M, Watson DK. Ets proteins in biological control and cancer. J Cell Biochem 2004;91:896-903.
44. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544.
45. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol 2005;6:R76.
46. Fan W, Huang X, Chen C, et al. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res 2004;64:5132-5139.
47. Sinclair CS, Adem C, Naderi A, et al. TBX2 is preferentially amplified in BRCA1-and BRCA2-related breast tumours. Cancer Res 2002;62:3587-3591.
48. Ghebranious N, Blank RD, Raggio CL, et al. A missense T (Brachyury) mutation contributes to vertebral malformations. J Bone Miner Res 2008;23:1576-1583.
49. Jensen LE, Barbaux S, Hoess K, et al. The human T locus and spina bifida risk. Hum Genet 2004;115:475-482.
50. Meisler MH. Mutation watch: mouse brachyury (T), the T-box gene family, and human disease. Mamm Genome 1997;8:799-800.
51. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11: 709-724.
52. Penault-Llorca F, Bertucci F, Adelaide J, et al. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995;61:170-176.
53. Sahadevan K, Darby S, Leung HY, et al. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007;213:82-90.
54. Scheil S, Bruderlein S, Liehr T, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001;32: 203-211.